UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000060231 |
|---|---|
| Receipt number | R000068149 |
| Scientific Title | Effects of Weekly Injection of Semaglutide on Vascular Endothelial Function in Japanese Patients with Type-2 Diabetes, A Retrospective Study |
| Date of disclosure of the study information | 2025/12/31 |
| Last modified on | 2025/12/29 13:08:43 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effects of Weekly Injection of Semaglutide on Vascular Endothelial Function in Japanese Patients with Type-2 Diabetes, A Retrospective Study
Acronym
Effects of Semaglutide on Endothelial Function
Scientific Title
Effects of Weekly Injection of Semaglutide on Vascular Endothelial Function in Japanese Patients with Type-2 Diabetes, A Retrospective Study
Scientific Title:Acronym
Effects of Semaglutide on Endothelial Function
Region
| Japan |
Condition
Condition
Japanese patients with type-2 diabetes
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
We examined the effects of weekly injection of Semaglutide on Vascular endothelial function in Japanese patients with type-2 DM.
Basic objectives2
Others
Basic objectives -Others
Effects of Semaglutide on HbA1c and body weight
Trial characteristics_1
Others
Trial characteristics_2
Others
Developmental phase
Not applicable
Assessment
Primary outcomes
Changes in endothelial function after therapy
Key secondary outcomes
Changes in HbA1c and Body weight
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 85 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
Patients admitted to Jinnouchi Hospital.
Patients were examined endothelial function by RH-PAT.
Semaglutide therapy was started during the hospitalization.
Key exclusion criteria
None
Target sample size
24
Research contact person
Name of lead principal investigator
| 1st name | Seigo |
| Middle name | |
| Last name | Sugiyama |
Organization
Jinnouchi Hospital
Division name
Diabetes Care Center
Zip code
862-0976
Address
6-2-3 Kuhonji Chuo-ku, Kumamoto City, Kumamoto Japan
TEL
0963630011
seigosugiyama@jinnouchi.or.jp
Public contact
Name of contact person
| 1st name | Seigo |
| Middle name | |
| Last name | Sugiyama |
Organization
Jinnouchi Hospital
Division name
Diabetes Care Center
Zip code
862-0976
Address
6-2-3 Kuhonji Chuo-ku, Kumamoto City, Kumamoto Japan
TEL
0963630011
Homepage URL
seigosugiyama@jinnouchi.or.jp
Sponsor or person
Institute
Jinnouchi Hospital
Institute
Department
Personal name
Seigo Sugiyama
Funding Source
Organization
Self Funding
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Jinnouchi Hospital
Address
6-2-3 Kuhonji Chuo-ku, Kumamoto City, Kumamoto Japan
Tel
0963630011
seigosugiyama@jinnouchi.or.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
熊本県
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2025 | Year | 12 | Month | 31 | Day |
Related information
URL releasing protocol
None
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
24
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2021 | Year | 01 | Month | 01 | Day |
Date of IRB
| 2025 | Year | 06 | Month | 30 | Day |
Anticipated trial start date
| 2021 | Year | 01 | Month | 01 | Day |
Last follow-up date
| 2025 | Year | 11 | Month | 02 | Day |
Date of closure to data entry
| 2025 | Year | 11 | Month | 05 | Day |
Date trial data considered complete
| 2025 | Year | 11 | Month | 07 | Day |
Date analysis concluded
| 2025 | Year | 11 | Month | 30 | Day |
Other
Other related information
Sugiyama S, Yoshida A, Kurinami N, et al. (December 24, 2025) Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study. Cureus 17(12): e99998. doi:10.7759/cureus.99998
Management information
Registered date
| 2025 | Year | 12 | Month | 29 | Day |
Last modified on
| 2025 | Year | 12 | Month | 29 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068149
